Related Experiment Video
Updated: Aug 5, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Rheumatoid arthritis-associated interstitial lung disease: Pathogenesis, risk stratification, and management
Rong Gao1, Siyan Liu1, Lixian Song1
1Department of Rheumatology and Immunology, Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University, Yantai, 264100, China.
Respiratory Medicine
|July 28, 2026
Summary
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a complex condition impacting rheumatoid arthritis patients. Understanding its varied causes and tailored treatments is crucial for better patient outcomes.
Area of Science:
- Rheumatology and Pulmonology
- Immunology and Genetics
- Pathophysiology of Lung Disease
Background:
- Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a significant complication of rheumatoid arthritis, contributing to morbidity and mortality.
- RA-ILD presents a spectrum from mild radiographic changes to severe, progressive fibrotic lung disease.
- The condition is biologically heterogeneous, involving autoimmunity, genetics, immune responses, and tissue repair.
Purpose of the Study:
- To review the current understanding of RA-ILD pathogenesis, risk factors, diagnosis, and treatment.
- To emphasize phenotype-oriented management strategies for RA-ILD.
- To highlight practical considerations for multidisciplinary care of RA-ILD patients.
Main Methods:
- Review of current evidence on RA-ILD pathogenesis and clinical manifestations.
- Analysis of diagnostic tools including high-resolution computed tomography (HRCT), pulmonary function tests, and biomarkers.
- Synthesis of current treatment strategies and guideline recommendations.
Main Results:
- RA-ILD arises from a complex interplay of genetic, immune, and environmental factors.
- Diagnosis relies on imaging (HRCT), functional tests, biomarkers, and multidisciplinary input.
- Management involves anti-inflammatory and antifibrotic therapies, tailored to disease phenotype and progression.
Conclusions:
- Effective RA-ILD management requires integrating inflammation and fibrosis assessment with personalized treatment approaches.
- Clinical decision-making is challenged by limited RA-ILD-specific trials and unclear progression definitions.
- Further research and standardized definitions are needed for optimal treatment sequencing and patient care.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:20Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...